Obesity Clinical Practice Guidelines Where we are and where we re going! Donna H. Ryan, MD
|
|
- Audra Mosley
- 5 years ago
- Views:
Transcription
1 Obesity Clinical Practice Guidelines Where we are and where we re going! Donna H. Ryan, MD
2 Disclosure Dr. Ryan has received financial remuneration for services rendered to Amgen, Eisai, Jansen, Novo Nordisk, Pfizer, Takeda, Vivus and Real Appeal and has ownership interest in Scientific Intake and Tulip Medical.
3 Guidelines, Guidelines, Guidelines > 44 countries have published guidelines targeting obesity In US, obesity guidelines from AHA/ACC/TOS 2013, AACE 2014, ENDO 2015, ASBP (OMA) 2015 US obesity guidelines overlap with Lifestyle Guidelines overlap in dietary and physical activity recommendations ACC/AHA Lifestyle Guidelines (2014) Dietary Guidelines for Americans (2015) Physical Activity Guidelines for Americans (2008)
4 US Guidelines for Obesity Clarity or Confusion?
5 Objectives Using 4 recent Guidelines as a basis, Describe the different approaches to clinical evaluations needed to identify patients who need medical intervention for weight loss; and Translate the recommendations for different treatment approaches into actionable steps for primary care offices in Lifestyle intervention Lifestyle intervention and pharmacotherapy Lifestyle intervention and bariatric surgery Discuss unmet needs and future directions
6 Where to find them Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity 2014;22(S2):S1-S410. AACE Advanced framework for a new diagnosis of obesity as a chronic disease. Available at Seger JC, Horn DB, Westman EC, Primack C, et al. Obesity Algorithm, presented by the American Society of Bariatric Physicians, Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100(2): All may be downloaded free of charge.
7 Primary Sources (Guidelines) in this talk. Obesity 2 ACC/AHA/TOS 2014 AACE Advanced Framework 2014 ASBP (OMA) annual ENDO Pharma Management 2015
8 Where to find them (for free) Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity 2014;22(S2):S1-S410. AACE Advanced framework for a new diagnosis of obesity as a chronic disease. Available at Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100(2): All may be downloaded free of charge from TOS, AACE and Endocrine Society websites.
9 The Good News These Guidelines target different audiences, are additive Obesity 2 Targets PCPs AACE Targets specialists ASBP Obesity Algorithm ENDO Pharmacotherapy Systematic Evidence Review Consensus of expert opinion Consensus of expert opinion Systematic Evidence Review Trustworthy authoritative with focus on 5 questions Focus on specialty approach to obesity as disease Detailed approach to weight management. Annual updates. 2 critical questions: meds that promote weight gain or weight loss
10 Let s look at some office scenarios; let s use the 4 sources to illustrate patient evaluation and treatment selection
11 How Do You Decide Who Needs Medical Intervention to Lose Weight?
12 Major Message from 2013 AHA/ACCC/TOS Guidelines It is imperative that PCPs engage in weight management as a pathway to better health for their patients. Screen with BMI at every visit. But BMI is only a screening tool. Waist circumference is a risk factor. Use the conventional cutpoints >35 inches for women and > 40 inches for men to identify patients that are high risk. Patients that are overweight and obese should be screened for CVD risk factors and comorbidities. Who needs to lose weight? BMI >30 kg/m 2 or BMI >25 kg/m 2 with a risk factor, like elevated waist circumference.
13 Staging the patient - the first step in the AACE Advanced Framework 1. Stage 0; BMI >25 or BMI >30, but no complications 2. Stage 1; BMI >25 or BMI >30 and mild/moderate complications 3. Stage 3; BMI > 25 or BMI >30 and at least one severe complication AACE Advanced framework. diagnosis-of-obesity-as-a-chronic-disease.pdf.
14 Major Message from AACE Framework Stage 0 obesity healthy diet, exercise pattern via lifestyle modification Stage 1 or 2 obesity* weight loss is important but 5-10% for stage 1 and >10% for stage 2. More intensity of weight loss effort is needed for more severe disease. * Designates BMI >25 kg/m 2
15
16 How do busy practitioners make this operational? BMI part of ehr WC only for BMI kg/m 2 BP part of vital signs Lipid profile, fasting glucose, A1c Symptom checklist You are already doing these things!
17 Another thing to note on the History form: Medications Diabetes Depression Neuropsychiatric problems HRT You are already doing these things!
18 How Much Weight Does the 1. 5% is enough 2. 10% is enough Patient Need to Lose? 3. The goal is the patient s decision. I say, Go for it. 4. It does not matter, because it will all be regained. 5. They must reach BMI <25.
19 Second Major Message from 2013 Obesity Guidelines You do not need to get all your patients to an ideal weight. Modest weight loss has major health benefits. Patients may do very well with lifestyle changes (diet and exercise). But if they struggle, we need to intensify approaches.
20 Obesity Guidelines: Recommendation 2 Grade A (Strong) Counsel patients about the benefits of weight loss: Lifestyle changes that produce modest (3% to 5%) sustained weight loss result in clinically meaningful health benefits - improvements in TG, glucose, HbA1c, and diabetes risk. Greater amounts of weight loss improve blood pressure, LDL-C, HDL-C, and reduce the need for medications to control blood glucose, blood pressure, and lipids, as well as further reduce TG and glucose. Note: most studies recommended a goal of 5% to 10% weight loss After 10-kg weight loss (85 kg, BMI 29)
21 Look AHEAD 1-year Data: Modest Weight Loss (5% to 10%) Improved CVD Markers Change in blood pressure (mm Hg) Diastolic Systolic Change in triglycerides (mg/dl) (mmol/l) Change in HDL and LDL (mg/dl) HDL LDL (mmol/l) LDL, P= Weight loss category Weight loss category Weight loss category Data presented as adjusted least square means and 95% CIs. Stable weight defined as ±2% of baseline weight. P< vs baseline for all weight categories,unless specified otherwise. Wing RR, et al. Diabetes Care. 2011;34(7):
22 Does this mean that we only need to target modest weight loss? No! AACE: Obesity with a serious complication warrants aggressive initial therapy: lifestyle + meds and consider bariatric surgery. ASBP: Goals are multiple improve health, improve quality of life, improve body weight and body composition The principle: the goal is improving targeted health goals through weight reduction
23 Modest Weight Loss Has Benefits, with Greater Weight Loss Associated with Greater Benefit Measures of glycemia 1 Triglycerides 1 and HDL cholesterol 1 Systolic and diastolic blood pressure Hepatic steatosis measured by MRS 2 Measures of feeling and function: Symptoms of urinary stress incontinence 5 Measures of sexual function 6,7 Quality of life measures (IWQOL) 8 NASH Activity Score measured on biopsy 3 Apnea-hypopnea index 4 Reduction in CV events, mortality, remission of T2DM 1. Wing et al. Diabetes Care 2011;34: Lazo et al. Diabetes Care 2010;33: Promrat et al. Hepatology 2010;51: Foster et al. Arch Intern Med 2009;169: % -5.0% -10.0% -15.0% 5. Phelan et al. Urol. 2012;187: Wing et al. Diab Care 2013;36: Wing et al. Journal of Sexual Medicine 2010 ; 7: Crosby, Manual for the IWQOL-LITE Measure 9. Sjostrom,et al
24 Your patient asks, My husband lost 20 pounds on the Wheat Belly Diet. Will this work for me? Your response is: 1. Yes, you should try it. 2. Yes, it will work as long as you follow it. 3. No. You must count calories. 4. Let s schedule some time to talk about weight loss? 5. I do not know. I have not read the book.
25 Third Major Message from 2013 Obesity Guidelines There is no magic diet for weight loss. Choose the diet composition based on the patient s health status and personal preference.
26 Obesity Guidelines: Recommendation 3 Grade A (Strong) Prescribe a diet to achieve reduced calorie intake, as part of a comprehensive lifestyle intervention. Use any one of the following methods: A to 1500 kcal/day for women and 1500 to 1800 kcal/day for men; B. Calculate energy requirements & subtract 500 to 750 kcal/day; or C. Prescribe one of the evidence-based diets that restricts certain food types (such as, high-carbohydrate foods, low-fiber foods, or high-fat foods)
27 Adherence Predicts Loss of Body Fat During Dieting Change in % Body Fat r=-0.74; p< Adherence to Diet Lyon XH, et al. Int J Obes Relat Metab Disord. 1995;19(4):
28 Does this mean that ANY diet is ok for weight loss, as long as its calorie reduced?
29 Diet Pattern Recommendations for LDL-C and BP Lowering Advise adults who would benefit from LDL-C or BP lowering to: Adapt this dietary pattern to appropriate calorie requirements, personal and cultural food preferences, and nutrition therapy for other medical conditions (including DM) Achieve this pattern by following plans such as the DASH dietary pattern, the US Department of Agriculture Food Pattern, or the AHA Diet Strength of evidence: Strong IA Eckel RH, et al. J Am Coll Cardiol. 2014;63:
30 Heart Healthy Nutrition and Physical Activity Behaviors for All Consume a dietary pattern that emphasizes intake of vegetables, fruits, and whole grains; includes low-fat dairy products, poultry, fish, legumes, nontropical vegetable oils, and nuts; and limits intake of sodium, sweets, sugarsweetened beverages, and red meats Adapt this dietary pattern to appropriate calorie requirements, personal and cultural food preferences, and nutrition therapy for other medical conditions, eg, DM Eckel RH, et al. J Am Coll Cardiol. 2014;63:
31 Fourth Major Message From 2013 Obesity Guidelines Losing weight requires honing a skill set of behaviors around diet and physical activity Everyone who needs to lose weight should have access to a comprehensive lifestyle intervention program with at least 14 sessions in 6 months and follow-up for 1 year If your patient does not have access to a comprehensive program in a medical or community setting, a commercial program with an evidence base to recommend it is acceptable Jensen MD, et al. Obesity. 2014;22:S Apovian CM, et al. J Clin Endocrinol Metab. 2015;100:
32 If I give my patient a diet sheet and exercise prescription, what are the odds that the patient will achieve 5% weight loss? 1) 1 in 5 2) 2 in 5 3) 3 in 5 4) 4 in 5 5) 100%, because my patients always take my advice
33 Obesity Guidelines: Recommendation 4 Grade A (Strong) Patients who need to lose weight should receive a comprehensive program (diet, physical activity, and behavior modification) of 6 months or longer The gold standard is on-site, high-intensity ( 14 sessions in 6 months) comprehensive intervention delivered in group or individual sessions by a trained interventionist and persisting for 1 year Other approaches (ie, Web-based, telephonic) may be used when patients cannot access the gold standard, although the amount of weight loss on average may be less (evidence grade B, moderate) Jensen MD, et al. Obesity. 2014;22:S Apovian CM, et al. J Clin Endocrinol Metab. 2015;100:
34 Major Messages About Lifestyle Intervention from 2013 Obesity Guidelines Losing weight requires honing a skill set of behaviors around diet and physical activity. Everyone who needs to lose weight should have access to a comprehensive lifestyle intervention program with 14 sessions in 6 months and follow-up for a year. If your patient does not have access to a comprehensive program in a medical or community setting, a commercial program with an evidence base to recommend it is acceptable. Jensen MD, et al. Obesity. 2014;22(S2):S1-S410.
35 Obesity Guidelines: Recommendation 4 Grade A (Strong) Patients who need to lose weight should receive a comprehensive program (diet, physical activity, and behavior modification) of 6 months or longer. The gold standard is on-site, high intensity (>14 sessions in 6 months) comprehensive intervention delivered in group or individual sessions by a trained interventionist and persisting for a year or more. Other approaches (ie, web-based, telephonic) may be used when patients cannot access the gold standard; albeit though, the amount of weight loss on average may be less. Jensen MD, et al. Obesity. 2014;22(S2):S1-S410.
36 What do the Guidelines say about patients who struggle? When do we add meds?
37 Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc Bariatric Surgery Pharmacotherapy Behavioral Modification to Change Diet, Physical Activity Guidance on medications which produce weight loss or are weight neutral But within the context of foundational treatment with diet, physical activity and behavior modification And recognizing that some patients benefit from bariatric surgery.
38 Prescribing Medications with a Weight Loss Indication from the ENDO Guidelines
39 Who Qualifies for Obesity Medications? Recommendation: Prescribe as an adjunct to diet, exercise and behavior modification for individuals with BMI 30+; or 27+ with comorbidity; who are unable to lose and successfully maintain weight; and who meet label indications. 1 (strong rec, high quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
40 When do you monitor and judge safety and efficacy? Suggestion: Assess efficacy and safety monthly for the first 3 months, then every 3 months thereafter. 2 (weak rec, low quality evidence) Recommendation: At 3 months, if loss is 5% or more, continue. If not, discontinue and seek alternative approaches. 1 (strong rec, high quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
41 How long should medications be used? Suggestion: For eligible patients, use mediations To promote long-term weight loss maintenance. 2 (weak rec, low quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
42 What dose should be used? Suggestion: Initiate and escalate dose (based on efficacy and tolerability) to the recommended dose and do not exceed upper approved dose boundaries. 2 (weak rec, low quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
43 Are there cautions with hypertension and cvd? Recommendation: In patients with uncontrolled hypertension and/or history of cvd, do not use sympathomimetic agents (phentermine and diethylpropion). 1 (strong rec, moderately high quality evidence) Suggestion: In patients with cardiovascular disease, use agents with no sympathomimetic action, such as lorcaserin and orlistat. 2 (weak rec, very low quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
44 Are there special issues with patients with type 2 diabetes? Suggestion: In patients with type 2 diabetes use antidiabetic medications that have additional actions to promote weight loss (GLP-1 analogs, SGLT-2 inhibitors in addition to the first line agent, metformin) 2 (weak rec, moderately high quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
45 Drugs that Cause Weight Gain and Alternative Approaches for Overweight and Obese Patients
46 Common Medications for Chronic Diseases and Weight Diabetes Weight Gain Associated With Use Insulin, sulfonylureas, TZDs, mitiglinide, sitagliptin? Alternatives (Weight Reducing in Parentheses) (Metformin), (acarbose), (miglitol), (pramlintide), (exenatide), (liraglutide), (SGLT-2 inhibitors) Hypertension medications α-blocker?, β-blocker? ACE inhibitors?, calcium channel blockers?, angiotensin-2 RAs Antidepressants and mood stabilizers Amytriptyline, doxepin, imipramine, nortriptyline, trimipramine, mirtazapine, fluoxetine?, sertraline?, paroxetine, fluvoxamine (Bupropion), nefazodone, fluoxetine (short term, sertraline, < 1 year) Oral contraceptives Progestational steroids Barrier methods, intrauterine devices? represents uncertain/under investigation. Apovian CM, et al. J Clin Endocrinol Metab. 2015;100:
47 Overweight and Obese Patients with Hypertension Recommendation: Use ACE inhibitors, ARBs and Ca channel blockers as first-line therapy, rather than beta blockers. 1 (strong rec, high quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
48 Patients with Overweight and Obesity Requiring Antidepressant, Antipsychotic or Antiepileptic Therapy Recommendation: Use a shared decision making process in selecting medication, providing patients with estimates of weight effects of medications. 1 (strong rec, moderately high quality evidence) Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
49 Antipsychotic and Anticonvulsant Medications and Weight Antipsychotics Anticonvulsants WEIGHT GAIN ASSOCIATED WITH USE Clozapine Risperidone Olanzapine Quetiapine Haloperidol Perphenazine Quetiapine Carbamazepine Gabapentin Valproate ALTERNATIVES (WEIGHT REDUCTING IN PARENTHESES)* Ziprasidone Aripiprizole Lamotrigine? (Topiramate) (Zonisamide) * Only phentermine/topiramate ER is FDA-approved for chronic weight management in patients with BMI 30+ kg/m 2 or BMI 27 <30 kg/m 2 with one or more comorbidities Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
50 Ungraded Best Practice Recommendation We suggest against the off-label use of medications approved for other disease states for the sole purpose of producing weight loss. Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
51 What does the Advanced Framework Say? Treatment based on clinical judgment Overweight / Obesity Stage 0 Obesity Stage 1 Obesity Stage 2 Healthy meal pattern Calorie restriction Physical activity Intensive Lifestyle / Behavioral Therapy? Medications Intensive Lifestyle / Behavioral Therapy + Medications Consider Bariatric Surgery AACE Advanced framework. diagnosis-of-obesity-as-a-chronic-disease.pdf.
52 How long should medications be used? From the ENDO Guidelines Suggestion: For eligible patients, use mediations To promote long-term weight loss maintenance. 2 Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacologic Management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015 doi: /jc
53 What do the 3 Guidelines say about bariatric surgery? They all agree!
54 ACC/AHA/TOS Obesity Guidelines: Recommendation 5 Grade A (Strong) Advise your patients with a BMI >35 kg/m 2 and a co-morbidity or >40 kg/m 2 that bariatric surgery may be an appropriate option to improve health and offer referral to an experienced bariatric surgeon for consultation and evaluation.
55 Are there gaps in Guidelines? Better advice on the healthy obese state BMI >30 and no risk factors based on systematic evidence review. Update the BMI limits for bariatric surgery, based on systematic evidence review. Recommendations on treatments that are ineffective or potentially harmful, baed on systematic evidence review.
56 That s your brief tour of the Guidelines. Just remember
57 Remember Your office is already doing many aspects of evaluation and staging. Treatment strategy is determined by severity/acuity of risk. You are already gathering info on medication use. A good start is prescribing wisely. Your job is to match the patient profile to the lifestyle and medication plan. Your job is also to be a proactive resource for patients who would benefit from bariatric surgery.
58 Thank you!
Let s s start with a case study.
Disclosure Dr. Ryan has received financial remuneration in 2015 from Amgen, Novo Nordisk, Janssen, Pfizer, Takeda, Vivus, Real Appeal, and Scientific Intake. Medicating the Patient with Obesity Clinical
More informationUsing New Guidelines to Improve Best Practices in Obesity Management
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationManagement of obesity
From Behavior Modification through Pharmacotherapy to Surgery an Emphasis on the Team Approach Scott D. Isaacs, M.D., F.A.C.P., F.A.C.E. drisaacs@atlantaendocrine.com Understand the physician s role in
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationReview of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home
604858PMTXXX10.1177/8755122515604858Journal of Pharmacy TechnologyCostello et al research-article2015 Case report Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home Journal
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationPRIMARY CARE MANAGEMENT OF OBESITY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences PRIMARY CARE MANAGEMENT OF OBESITY LYDIA CHWASTIAK MD, MPH ASSOCIATE PROFESSOR UNIVERSITY OF WASHINGTON DEPARTMENT
More informationTreatment Options for Obesity: Lifestyle and Pharmacotherapy
Treatment Options for Obesity: Lifestyle and Pharmacotherapy Daniel Bessesen, MD Professor of Medicine University of Colorado, School of Medicine Denver, Colorado USA Daniel.Bessesen@ucdenver.edu Question
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationObesity Management in Type 2 Diabetes
Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe
More informationDietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes. Stephen D. Sisson MD
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
More informationPart 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.
Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationDisclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014
Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationCOMBINATION OF PHENTERMINE/TOPIRAMATE ER AND LIRAGLUTIDE 3MG FOR INTENSIVE THERAPY OF SEVERE OBESITY & T2DM A CASE SERIES AND BRIEF REVIEW
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationEffective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.
Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could
More informationThe prevalence of obesity in adults has doubled over the past 30 years
Obesity in America: Facts and Fiction MICHAEL G. PERRI, PhD Professor, Clinical and Health Psychology Interim Dean, College of Public Health and Health Professions University of Florida Overview: Key Questions
More informationSession 21: Heart Health
Session 21: Heart Health Heart disease and stroke are the leading causes of death in the world for both men and women. People with pre-diabetes, diabetes, and/or the metabolic syndrome are at higher risk
More informationHealthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40
A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 10, Issue 4 Winter 2015 T he American Medical Association, the World Health Organization, and the US Food and Drug Administration
More informationEngaging Pharmacotherapy and Behavioral Interventions to Maximize Post-Procedure Weight Loss
Engaging Pharmacotherapy and Behavioral Interventions to Maximize Post-Procedure Weight Loss Louis J. Aronne, MD, FACP, FTOS, DABOM Sanford I Weill Professor of Metabolic Research Weill Cornell Medical
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationDisclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None
Disclosures None OBESITY Florencia Halperin, M.D. Medical Director, Program for Management Brigham and Women s Hospital Instructor in Medicine, Harvard Medical School Overview Obesity: Definition Definition
More informationAn Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
More informationMedical Management of the Patient with Obesity: Using drugs, devices and surgery to improve health
Donna H. Ryan, MD Executive Director Pennington Biomemedical Research Center Baton Rouge, LA, USA Medical Management of the Patient with Obesity: Using drugs, devices and surgery to improve health Disclosures
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationLearning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
More informationAmerican Diabetes Association: Standards of Medical Care in Diabetes 2015
American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform
More informationMedications that Can Cause Weight Gain
Medications that Can Cause Weight Gain Derrick Cetin, D.O. Obesity Medicine Clinical Assistant Professor Dept. of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationSTATE OF THE STATE: TYPE II DIABETES
STATE OF THE STATE: TYPE II DIABETES HENRY DRISCOLL, MD, CHIEF of ENDOCRINOLOGY MARSHALL U, CHERTOW DIABETES CENTER, HUNTINGTON VAMC HEATHER VENOY, RD, LD, CDE DIETITIAN, DIABETES EDUCATOR, CHERTOW DIABETES
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationMedical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy Shelby Sullivan University of Colorado School Of Medicine Disclosures Research Support / Grants R01DK094483-02 Klein/Mittendorfer
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationOBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest CLASSIFICATION OF OVERWEIGHT
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationNew Food Label Pages Diabetes Self-Management Program Leader s Manual
New Food Label Pages The FDA has released a new food label, so we have adjusted Session 4 and provided a handout of the new label. Participants use the handout instead of looking at the label in the book
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationScreening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016
Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October
More informationPrimary Outcome Results of DiRECT the Diabetes REmission Clinical Trial
Finding a practical management solution for T2DM, in primary care Primary Outcome Results of DiRECT the Diabetes REmission Clinical Trial Mike Lean, Roy Taylor, and the DiRECT Team IDF Abu Dhabi, December
More informationHealth Score SM Member Guide
Health Score SM Member Guide Health Score Your Health Score is a unique, scientifically based assessment of seven critical health indicators gathered during your health screening. This number is where
More informationOverweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University
Overweight and Obesity on the Menu Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University Prevention The most efficient and cost-effective approach
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationNUTRITION INTERVENTIONS FOR WEIGHT LOSS. Paul Blakeslee RD, LD, CNSC September 17 th 2017
NUTRITION INTERVENTIONS FOR WEIGHT LOSS Paul Blakeslee RD, LD, CNSC September 17 th 2017 Disclosures None. Objectives Compare and contrast popular diets and evidenced based diets as part of a patients
More informationJoslin Diabetes Center Management of Diabetes in 2013: The Need to Combine Art and Science Weight Management in the Patient With Diabetes
Long-term Weight Management in Patients With Diabetes: The Why WAIT Model Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program Director of Inpatient Diabetes Management Joslin Diabetes
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationHow does the LIFESTEPS Weight Management Program support diabetes prevention?
LIFESTEPS and Diabetes Prevention How does the LIFESTEPS Weight Management Program support diabetes prevention? The LIFESTEPS Weight Management Program (LIFESTEPS ) is a cognitive-behavioral program designed
More informationMacronutrients and Dietary Patterns for Glucose Control
제 20 회대한당뇨병학회춘계학술대회 Macronutrients and Dietary Patterns for Glucose Control 2017.5.13 서울대학교병원임정현 Conflict of interest disclosure None Committee of Scientific Affairs Contents Review of Nutrition Recommendation
More informationNutritional Aspects of Obesity Management. Christy Olson MS, RD, LD, CDE
Nutritional Aspects of Obesity Management Christy Olson MS, RD, LD, CDE Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made
More informationLosing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise.
OBESITY Treatment Losing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise. If you ve tried on your own and still find that you
More informationManagement of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE
Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent
More informationOBESITY VA/DOD CLINICAL PRACTICE GUIDELINE FOR SCREENING AND MANAGEMENT OF OVERWEIGHT AND OBESITY. Guideline Summary
VA/DOD CLINICAL PRACTICE GUIDELINE FOR SCREENING AND MANAGEMENT OF OVERWEIGHT AND OBESITY Department of Veterans Affairs Department of Defense Guideline Summary KEY ELEMENTS ADDRESSED BY THE GUIDELINE
More informationHow to Achieve Medical Weight Loss in 2012
How to Achieve Medical Weight Loss in 2012 Gary D. Foster, Ph.D. Laure H. Carnell Professor of Medicine, Public Health, and Psychology Director, Center for Obesity Research and Education Temple University
More informationManaging Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationOBESITY IN PRIMARY CARE
OBESITY IN PRIMARY CARE Obesity- definition Is a chronic disease In ICD 10 E66 Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Obesity is a leading
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationRealistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013
Realistic Expectations: Drugs in the Treatment of Obesity Lora Cotton, D.O. January 20, 2013 Overview Approach FDA approved agents will be covered FDA approval guidelines Candidates Expectations Mechanisms,
More informationHow do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian
How do we adapt diet approaches for patients with obesity with or without diabetes? Therese Coleman Dietitian Developing a specialist weight management programme How did we adapt dietary approaches for
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationBuilding Our Evidence Base
Plant-Based Diets Neal D. Barnard, MD, FACC Adjunct Associate Professor of Medicine George Washington University School of Medicine Physicians Committee for Responsible Medicine Washington, DC Building
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationMetabolic Monitoring, Schizophrenia Spectrum Illnesses, & Second Generation Antipsychotics
Metabolic Monitoring, Schizophrenia Spectrum Illnesses, & Second Generation Antipsychotics National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationMedical Nutrition Therapy Options for Adults Living with Diabetes. Jane Eyre Schuster, RD, LD, CDE Legacy Health Diabetes and Nutrition Services
Medical Nutrition Therapy Options for Adults Living with Diabetes Jane Eyre Schuster, RD, LD, CDE Legacy Health Diabetes and Nutrition Services Objectives Discuss Medical Nutrition Therapy considerations
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationPreventing Diabetes K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y
Preventing Diabetes 2018 K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y D A V I D G E F F E N S C H O O L O F M E D I C I N E A T U C L A CO-DIRECTOR,
More informationFaculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
More informationOverview Purpose Complete the Qsymia Pharmacy Certification in 3 easy steps:
Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia to ensure the benefits of Qsymia outweigh the increased risk of teratogenicity.
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationImpact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationUnderstanding Obesity: The Causes, Effects, and Treatment Options
Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,
More informationClinical Prevention Initiative
Clinical Prevention Initiative Report on the medical practice reporting needs and evidence-based strategies for cardiovascular and geriatric risk interventions L. Olivia Hopkins, Charlie Bennett, Christian
More informationRICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT Carmarthenshire County Council
RICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT 2016 Carmarthenshire County Council WHY LEAD A HEALTHY LIFESTYLE? A nutritious, well-balanced diet along with physical activity and refraining from smoking
More informationCase Study #4: Hypertension and Cardiovascular Disease
Helen Jang Tara Hooley John K Rhee Case Study #4: Hypertension and Cardiovascular Disease 7. What risk factors does Mrs. Sanders currently have? The risk factors that Mrs. Sanders has are high blood pressure
More informationWithout Background for printing as Pocket Reference
Without Background for printing as Pocket Reference Diabetes Prevention Program 1 LOOK AHEAD 3 Multi-center trial in patients with impaired glucose tolerance Weight loss of 7% reduced the rate of progression
More informationIntervention Recommendations with Class of Recommendation and Level of Evidence
Intervention Recommendations with Class of Recommendation and Level of Evidence RISK: BLOOD PRESSURE CONTROL: LIPID Goal: to identify people who will benefit from risk reduction strategies Goal:
More informationMetabolic Syndrome Across the Life Cycle - Adolescent. Joy Friedman MD
Metabolic Syndrome Across the Life Cycle - Adolescent Joy Friedman MD Disclosures I have no actual or potential conflict of interest in relation to this program or presentation. I will mention off-label
More informationSession 21 Leader Guide: Heart Health
Session 21 Leader Guide: Heart Health Objectives In this session, the participants will: Identify the leading cause of death in American adults. Define heart disease. Learn the risk factors for heart disease.
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationFor Asian individuals the BMI numbers are 27.5 and 25 respectively These values are from the NICE guidelines of 2014
Ken Cathcart DO FACE We need to define several things to start the talk Obesity is defined medically as a BMI of greater than 30 or a BMI >27 with co-morbidities such as hypertension, type 2 DM, dyslipidemia,
More informationIntroduction. Objectives. Psychotropic Medications & Cardiometabolic Risk
Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved
More informationOverview. Purpose. Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program
Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS)
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationTreating Type 2 Diabetes by Treating Obesity. Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition
Treating Type 2 Diabetes by Treating Obesity Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition 2 Center Stage Obesity is currently an epidemic in the United States, with
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationA Needs Assessment of Hypertension in Georgia
A Needs Assessment of Hypertension in Georgia Faye Lopez Mercer University School of Medicine Marylen Rimando Mercer University School of Medicine Harshali Khapekar Mercer University School of Medicine
More informationTo reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.
E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationObjectives. Medical Nutrition Therapy (MNT) for Diabetes Evidence-based Recommendations. No financial disclosures
Medical Nutrition Therapy (MNT) for Diabetes Evidence-based Recommendations Advances in Internal Medicine 2013 Sarah Kim, MD Assistant Clinical Professor, UCSF-SFGH No financial disclosures Objectives
More informationBROUGHT TO YOU BY. Blood Pressure
BROUGHT TO YOU BY Blood Pressure High blood pressure usually has no warning signs or symptoms, so many people don't realize they have it. According to the Center of Disease Control, CDC, about 75 million
More information